Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Osimertinib (TAGRISSO) (ROSY-T) - ROSY-T

Study identifier:D5161N00007

ClinicalTrials.gov identifier:NCT05629234

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

ROSY-T: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Osimertinib and are Judged by the Investigator to Clinically Benefit From Continued Treatment

Medical condition

cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Osimertinib

Sex

All

Estimated Enrollment

52

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 08 May 2023
Estimated Primary Completion Date: 21 Feb 2025
Estimated Study Completion Date: 21 Feb 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria